BBAR vs TCBI

BBAR exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite strong long-term price appreciation, the stock trades at a premium valuation (P/E 30.28 vs sector avg 21.03) while facing sharp declines in revenue (-17.70% YoY) and earnings (-75.5% YoY). Earnings quality is poor, with 3 of the last 4 quarters missing estimates by an average of -45.13%, and key metrics like ROE (7.19%) and ROA (1.11%) remain below industry benchmarks. The lack of Altman Z-Score data raises transparency concerns, but the deterministic scorecard and deteriorating trends support a bearish outlook.

TCBI presents a compelling growth story with a Piotroski F-Score of 4/9, indicating stable financial health. The stock is currently trading slightly below its Graham Number ($107.87), suggesting a defensive fair value, while its intrinsic value ($202.66) points to significant long-term upside driven by explosive earnings growth. Despite a bearish technical trend score, the actual price performance is strongly positive, and recent quarterly earnings beats (3 of last 4) underscore a powerful recovery phase.